Page 27 - TD-1-1

Tumor Discovery Monocytes from single-cell analysis

https://doi.org/10.3389/fimmu.2018.01977 https://doi.org/10.1146/annurev.immunol.26.021607.090331
118. Nywening TM, Wang-Gillam A, Sanford DE, et al., 2016, 129. Topalian SL, Drake CG, Pardoll DM, 2015, Immune
Targeting tumour-associated macrophages with CCR2 checkpoint blockade: A common denominator approach to
inhibition in combination with FOLFIRINOX in patients cancer therapy. Cancer Cell, 27(4): 450–461.
with borderline resectable and locally advanced pancreatic https://doi.org/10.1016/j.ccell.2015.03.001
cancer: A single-centre, open-label, dose-finding, non-
randomised, phase 1b trial. Lancet Oncol, 17(5): 651–662. 130. Schetters ST, Rodriguez E, Kruijssen LJ, et al., 2020,
Monocyte-derived APCs are central to the response of PD1
https://doi.org/10.1016/S1470-2045(16)00078-4 checkpoint blockade and provide a therapeutic target for
119. Bonapace L, Coissieux MM, Wyckoff J, et al., 2014, Cessation combination therapy. J Immunother Cancer, 8(2): e000588.
of CCL2 inhibition accelerates breast cancer metastasis by https://doi.org/10.1136/jitc-2020-000588
promoting angiogenesis. Nature, 515(7525): 130–133.
131. Hugo W, Zaretsky JM, Sun L, et al., 2016, Genomic and
https://doi.org/10.1038/nature13862 transcriptomic features of response to anti-PD-1 therapy in
120. Steggerda SM, Bennett MK, Chen J, et al., 2017, Inhibition of metastatic melanoma. Cell, 165(1): 35–44.
arginase by CB-1158 blocks myeloid cell-mediated immune https://doi.org/10.1016/j.cell.2016.02.065
suppression in the tumor microenvironment. J Immunother.
Cancer, 5(1): 101. 132. Hamid O, Robert C, Daud A, et al., 2013, Safety and tumor
responses with lambrolizumab (anti-PD-1) in melanoma.
https://doi.org/10.1186/s40425-017-0308-4 N Engl J Med, 369(2): 134–144.
121. Nefedova Y, Fishman M, Sherman S, et al., 2007, Mechanism https://doi.org/10.1056/NEJMoa1305133
of all-trans retinoic acid effect on tumor-associated myeloid-
derived suppressor cells. Cancer Res, 67(22): 11021–11028. 133. Das S, Camphausen K, Shankavaram U, 2020, Cancer-
specific immune prognostic signature in solid tumors and
https://doi.org/10.1158/0008-5472.CAN-07-2593 its relation to immune checkpoint therapies. Cancers, 12(9):

122. Vincent J, Mignot G, Chalmin F, et al, 2010, 5-fluorouracil 2476.
selectively kills tumor-associated myeloid-derived https://doi.org/10.3390/cancers12092476
suppressor cells resulting in enhanced T cell-dependent
antitumor immunity. Cancer Res, 70(8): 3052–3061. 134. Marcovecchio PM, Thomas G, Salek-Ardakani S, 2021,
CXCL9-expressing tumor-associated macrophages: New
https://doi.org/10.1158/0008-5472.CAN-09-3690 players in the fight against cancer. J Immunother Cancer,
123. Dempke WC, Fenchel K, Uciechowski P, et al., 2017, 9(2): e002045.
Second-and third-generation drugs for immuno-oncology https://doi.org/10.1136/jitc-2020-002045
treatment-the more the better? Eur J Cancer, 74: 55–72.
135. Huber V, Di Guardo L, Lalli L, et al., 2021, Back to simplicity:
https://doi.org/10.1016/j.ejca.2017.01.001 A four-marker blood cell score to quantify prognostically
124. Mellman I, Coukos G, Dranoff G, 2011, Cancer relevant myeloid cells in melanoma patients. J Immunother
immunotherapy comes of age. Nature, 480(7378): 480–489. Cancer, 9(2): e001167.
https://doi.org/10.1038/nature10673 https://doi.org/10.1136/jitc-2020-001167
136. Gordon SR, Maute RL, Dulken BW, et al., 2017, PD-1
125. Drake CG, Jaffee E, Pardoll DM, 2006, Mechanisms of
immune evasion by tumors. Adv Immunol, 90: 51–81. expression by tumour-associated macrophages inhibits
phagocytosis and tumour immunity. Nature, 545(7655):
https://doi.org/10.1016/S0065-2776(06)90002-9 495–499.
126. van der Leun AM, Thommen DS, Schumacher TN, 2020, https://doi.org/10.1038/nature22396
CD8 T cell states in human cancer: Insights from single-cell
analysis. Nat Rev Cancer, 20(4): 218–232. 137. Zou W, Wolchok JD, Chen L, 2016, PD-L1 (B7-H1) and
PD-1 pathway blockade for cancer therapy: Mechanisms,
https://doi.org/10.1038/s41568-019-0235-4 response biomarkers, and combinations. Sci Transl Med,
127. Ribas A, Wolchok JD, 2018, Cancer immunotherapy using 8(328): 328–324.
checkpoint blockade. Science (New York), 359(6382): 1350– https://doi.org/10.1126/scitranslmed.aad7118
1355.
138. Liu M, Zhou J, Liu X, et al., 2020, Targeting monocyte-
https://doi.org/10.1126/science.aar4060 intrinsic enhancer reprogramming improves
128. Keir ME, Butte MJ, Freeman GJ, et al., 2008, PD-1 and its immunotherapy efficacy in hepatocellular carcinoma. Gut,
ligands in tolerance and immunity. Annu Rev Immunol, 69(2): 365–379.
26: 677–704. https://doi.org/10.1136/gutjnl-2018-317257

Volume 1 Issue 1 (2022) 18 https://doi.org/10.36922/td.v1i1.4